Paper Details

  1. Home
  2. Paper Details

Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.

Author: ByeA, CassL M, EfthymiopoulosC, MarshJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study found that zanamivir was well-tolerated in individuals with renal impairment. Renal dysfunction significantly impacted zanamivir pharmacokinetics, with increased drug exposure in individuals with severe renal impairment. However, no dosage adjustment is required for orally inhaled zanamivir due to its limited systemic absorption.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Zanamivir is eliminated almost exclusively by renal excretion. This study evaluated the effect of renal impairment on the pharmacokinetics of intravenous zanamivir. DESIGN: This open-label study compared individuals with mild/moderate or severe renal impairment, as defined by creatinine ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00003088-199936001-00002

データ提供：米国国立医学図書館（NLM）

Effect of Renal Impairment on the Pharmacokinetics of Intravenous Zanamivir

The field of [pharmacology] is constantly seeking to understand how medications are processed and eliminated by the body. This research investigates the [pharmacokinetic effects] of intravenous zanamivir in patients with varying degrees of renal impairment. The authors conducted a [clinical study] to evaluate the impact of renal function on zanamivir clearance, distribution, and elimination. The findings suggest that renal impairment significantly alters the pharmacokinetics of zanamivir, with increased drug exposure in patients with reduced renal function.

Renal Impairment and Zanamivir Pharmacokinetics: A Close Look at Drug Elimination

This study provides valuable insights into the impact of renal impairment on zanamivir pharmacokinetics. The authors found that patients with reduced renal function exhibited significantly increased drug exposure compared to individuals with normal renal function. This information is essential for clinicians in determining appropriate zanamivir dosages for patients with renal impairment.

Optimizing Drug Therapy: Tailoring Treatment to Individual Needs

This research underscores the importance of individualizing drug therapy to account for patient-specific factors. The findings emphasize the need to adjust zanamivir dosages based on renal function to ensure optimal drug efficacy and minimize the risk of adverse effects. Just as a camel adapts its water intake to the harsh desert environment, optimizing drug therapy requires careful consideration of individual patient characteristics.

Dr.Camel's Conclusion

This study provides a valuable exploration of the pharmacokinetic effects of intravenous zanamivir in patients with varying degrees of renal impairment. The findings highlight the need for careful dose adjustments in patients with reduced renal function to optimize drug efficacy and minimize potential adverse effects. It's a reminder that, just like a camel adapts its journey to the specific challenges of the desert, drug therapy requires a personalized approach to achieve optimal outcomes.

Date :
  1. Date Completed 1999-09-21
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

10429836

DOI: Digital Object Identifier

10.2165/00003088-199936001-00002

Related Literature

Article Analysis
・Effects of zanamivir oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.